Sarepta Therapeutics, Inc.

SRPT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2009
Operating Activities
Net Income $-25.2M
Depreciation & Amortization $1.4M
Depreciation —
Amortization —
Stock-Based Compensation $2.4M
Net Cash from Operating Activities $-8.8M
Investing Activities
Capital Expenditures $931.0K
Business Acquisitions —
Net Cash from Investing Activities $-1.9M
Financing Activities
Dividends Paid —
Stock Repurchases —
Net Cash from Financing Activities $47.8M
Net Change in Cash $37.1M
Free Cash Flow $-9.7M
← Newer Page 3 of 3 Older →